RxDoctor Payments DataLook up a doctor →

Hatim Husain, MD

Internal Medicine · San Diego, CANPI 1629234109

Payments from drug & device makers

$2,602,697in general payments, 2019–2025

Across 1,714 payments — averaging $1518.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$651K
  • Roche Sequencing Solutions, Inc.$246K
  • Johnson & Johnson$245K
  • Foundation Medicine, Inc.$193K
  • Pfizer$191K
  • EMD Serono, Inc.$176K
  • plus $900K from 28 others
$42,120in research payments, 2019–2025

Across 15 payments — averaging $2807.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$32K
  • Pfizer$10K
  • Regeneron$1K

What the payments were for

  • Consulting fees$464,89523%
  • Speaking & faculty fees$1,280,39263%
  • Travel & lodging$237,26112%
  • Food & beverage$36,9152%
  • Education$790%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,602,697 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$175,897
Medicare patients
167
Services billed
1,940

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate227$3,635,791
RetevmoSelpercatinib23$496,142
VitrakviLarotrectinib Sulfate11$402,698
LorbrenaLorlatinib14$278,860
AlecensaAlectinib Hcl15$275,126
LumakrasSotorasib12$250,020
GilotrifAfatinib Dimaleate22$221,099
EliquisApixaban59$35,530
Dexamethasone28$335
Prochlorperazine Maleate29$265
Ondansetron OdtOndansetron12$169
Ondansetron Hcl32$164
Lidocaine Hcl ViscousLidocaine Hcl12$135
Oxycodone Hcl11$58
Folic Acid12$30

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$651,491$3,635,791227 claims
BayerVitrakvi$5,800$402,69811 claims
PfizerLorbrena, Eliquis$191,199$314,39073 claims
AmgenLumakras$56,559$250,02012 claims
Boehringer IngelheimGilotrif$2,130$221,09922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →